Brought to you by 
Astellas and Medivation develop prostate cancer candidate
18 Dec 2019
Executive Summary
Astellas Pharma and Medivation (drugs for serious diseases) have entered into a worldwide co-development and co-commercialization agreement for the latter's MDV3100, a Phase III oral anti-androgen for castration-resistant prostate cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas and Medivation develop prostate cancer candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice